BioSupply Trends Quarterly logo
Close this search box.
Winter 2020 - Integrated Care

New Rabies Calculator Helps Providers Treat Patients Exposed to Rabies

Kedrion Biopharma has created the KEDRAB Dose Calculator to help healthcare providers treat rabies exposures. The free, easy-to-use online tool prompts healthcare providers to input the weight of a patient who has been exposed to rabies, and the tool then calculates the precise KEDRAB dose needed.

KEDRAB is a human rabies immune globulin (HRIG) indicated for postexposure prophylaxis (PEP) of rabies infection. Administered concurrently with a full course of rabies vaccine, HRIG is an important component of rabies PEP for previously unvaccinated persons. PEP is a highly effective treatment regimen issued by the Centers for Disease Control and Prevention and the Advisory Committee on Immunization Practices (ACIP). Rabies is almost always fatal when left untreated. However, by administering rabies PEP promptly and properly, healthcare professionals can prevent the onset of rabies symptoms. When administered according to ACIP guidelines, PEP is essentially 100 percent effective in preventing human rabies.

“Rabies is a medical urgency and care should not be delayed. Because rabies is a fatal disease, there is no room for treatment error when a person exposed to rabies presents at the emergency room or clinic,” said Peter Costa, MPH, MCHES, AVES (Hon), rabies immunoglobulin brand director at Kedrion Biopharma. “The KEDRAB Dose Calculator was created to help clinicians quickly and accurately dose KEDRAB, which is a critical component of the rabies post-exposure prophylaxis regimen.”


New KEDRAB Dose Calculator Launches to Help Hospitals in Treating Rabies Exposures. Kedrion Biopharma press release, Aug. 7, 2019. Accessed at

BSTQ Staff
BioSupply Trends Quarterly [BSTQ] is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace. With timely and critical information, each themed issue covers topics ranging from product breakthroughs, industry insights and innovations, up-to-the-minute news on the latest clinical trials, accessibility, and service and safety concerns.